These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23957510)

  • 1. Evaluation of discordance measures in oncology studies with blinded independent central review of progression-free survival using an observational error model.
    Mannino FV; Amit O; Lahiri S
    J Biopharm Stat; 2013; 23(5):971-85. PubMed ID: 23957510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.
    Stone AM; Bushnell W; Denne J; Sargent DJ; Amit O; Chen C; Bailey-Iacona R; Helterbrand J; Williams G;
    Eur J Cancer; 2011 Aug; 47(12):1763-71. PubMed ID: 21435858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of audit methodologies for bias evaluation of tumor progression in oncology clinical trials.
    Zhang JJ; Zhang L; Chen H; Murgo AJ; Dodd LE; Pazdur R; Sridhara R
    Clin Cancer Res; 2013 May; 19(10):2637-45. PubMed ID: 23532893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis.
    Amit O; Mannino F; Stone AM; Bushnell W; Denne J; Helterbrand J; Burger HU
    Eur J Cancer; 2011 Aug; 47(12):1772-8. PubMed ID: 21429737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of statistical issues with progression-free survival as an interval-censored time-to-event endpoint.
    Sun X; Li X; Chen C; Song Y
    J Biopharm Stat; 2013; 23(5):986-1003. PubMed ID: 23957511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Missing data and censoring in the analysis of progression-free survival in oncology clinical trials.
    Denne JS; Stone AM; Bailey-Iacona R; Chen TT
    J Biopharm Stat; 2013; 23(5):951-70. PubMed ID: 23957509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing temporal agreement between central and local progression-free survival times.
    Zeng D; Cornea E; Dong J; Pan J; Ibrahim JG
    Stat Med; 2015 Feb; 34(5):844-58. PubMed ID: 25393731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testing of evaluation bias for progression free survival endpoint in oncology clinical trials.
    Sun Y; Wu W; Sargent D
    Stat Med; 2016 Sep; 35(22):3923-32. PubMed ID: 27089832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is it time to abandon complete blinded independent central radiological evaluation of progression in registration trials?
    Pignatti F; Hemmings R; Jonsson B
    Eur J Cancer; 2011 Aug; 47(12):1759-62. PubMed ID: 21641204
    [No Abstract]   [Full Text] [Related]  

  • 10. Model free audit methodology for bias evaluation of tumour progression in oncology.
    Stone A; Macpherson E; Smith A; Jennison C
    Pharm Stat; 2015; 14(6):455-63. PubMed ID: 26435269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statistical methods for a phase II oncology trial with a growth modulation index (GMI) endpoint.
    Kovalchik S; Mietlowski W
    Contemp Clin Trials; 2011 Jan; 32(1):99-107. PubMed ID: 20920605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trials.
    Sridhara R; Mandrekar SJ; Dodd LE
    Clin Cancer Res; 2013 May; 19(10):2613-20. PubMed ID: 23669421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Research outcomes and recommendations for the assessment of progression in cancer clinical trials.
    Bushnell W; Stone A
    J Biopharm Stat; 2013; 23(5):949-50. PubMed ID: 23957508
    [No Abstract]   [Full Text] [Related]  

  • 14. How is retrospective independent review influenced by investigator-introduced informative censoring: a quantitative approach.
    Fleischer F; Gaschler-Markefski B; Bluhmki E
    Stat Med; 2011 Dec; 30(29):3373-86. PubMed ID: 21953353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating and adjusting for premature censoring of progression-free survival.
    Rothmann M; Koti K; Lee KY; Lu HL; Shen YL; Zhang JJ; Jin M; Zhou H
    J Biopharm Stat; 2013; 23(5):1091-105. PubMed ID: 23957518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of progression-free survival data using a discrete time survival model that incorporates measurements with and without diagnostic error.
    Hunsberger S; Albert PS; Dodd L
    Clin Trials; 2010 Dec; 7(6):634-42. PubMed ID: 21109582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating co-primary endpoints collectively in clinical trials.
    Li QH
    Biom J; 2009 Feb; 51(1):137-45. PubMed ID: 19219905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity analysis of progression-free survival with dependent withdrawal.
    Ruan PK; Gray RJ
    Stat Med; 2008 Apr; 27(8):1180-98. PubMed ID: 17768718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statistical considerations for the next generation of clinical trials.
    Wu W; Shi Q; Sargent DJ
    Semin Oncol; 2011 Aug; 38(4):598-604. PubMed ID: 21810519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Blinded Independent Central Review of Tumor Progression in Oncology Clinical Trials: A Meta-analysis.
    Zhang JJ; Chen H; He K; Tang S; Justice R; Keegan P; Pazdur R; Sridhara R
    Ther Innov Regul Sci; 2013 Mar; 47(2):167-174. PubMed ID: 30227523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.